SCHEMBL20116320

SCHEMBL20116320

CC(C)(C)OC(=O)N1CC(c2noc(-c3ccc4cnn(C5COC5)c4c3)n2)C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 3/20 0.45
GPR119 Q8TDV5 4/20 0.42
TBK1 Q9UHD2 4/20 0.42
HDAC4 P56524 4/20 0.37
HDAC6 Q9UBN7 2/20 0.37
SCD5 Q86SK9 1/20 0.36
LRRK2 Q5S007 1/20 0.36
PIK3CA P42336 1/20 0.35
MTOR P42345 1/20 0.35
PIK3CG P48736 1/20 0.35
ATR Q13535 1/20 0.35
AURKB Q96GD4 1/20 0.35
KDM4E B2RXH2 1/20 0.35
NPC1 O15118 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
RAB9A P51151 1/20 0.35
HSD17B10 Q99714 1/20 0.35
IKBKE Q14164 1/20 0.35
JAK1 P23458 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20116041 0.92 GPR119 (0.49) USP30GPR119TBK1HDAC4HDAC6
SCHEMBL20116980 0.91 USP30 (0.40) USP30SCD5PIK3CAMTORKDM4E
SCHEMBL20117085 0.90 USP30 (0.47) USP30GPR119TBK1HDAC4HDAC6
SCHEMBL20676590 0.89 TBK1 (0.41) USP30GPR119TBK1HDAC4SCD5
SCHEMBL20676725 0.86 GPR119 (0.47) USP30GPR119TBK1HDAC4PIK3CA
SCHEMBL22358156 0.86 GPR119 (0.47) USP30GPR119TBK1HDAC4PIK3CA
SCHEMBL20116304 0.86 GPR119 (0.47) USP30GPR119TBK1HDAC4PIK3CA
SCHEMBL20116173 0.86 USP30 (0.39) USP30TBK1SCD5KDM4ENPC1
SCHEMBL20117097 0.85 GRM5 (0.44) GPR119HDAC4HDAC6
SCHEMBL20676318 0.85 USP30 (0.41) USP30GPR119TBK1LRRK2PIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-20200262828-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2020-08-20 US disclosed
WO-2019209948-A9 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. (US) 2020-01-02 WO disclosed
WO-2019018795-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2019-01-24 WO disclosed
WO-2018081167-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2018-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873298-B2 Compounds and uses thereof NLN, ACHE, CLN6 USP30 3526/4885GPR119 2922/4885TBK1 3534/4885
US-20200262828-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 USP30 3526/4885GPR119 2922/4885TBK1 3534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.